Pleural mesothelioma (PM) is a rare, aggressive malignancy of the lung lining, primarily caused by asbestos exposure. Its long latency period and late-stage diagnosis contribute to a poor prognosis, with five-year survival rates below 5%. While chemotherapy has been the historical standard, it offers limited benefit. Immune checkpoint inhibitors (ICIs) have recently shown promise by reactivating anti-tumour immunity, yet only a subset of patients responds, and resistance commonly develops. Concurrently, anti-angiogenic therapies targeting VEGF/VEGFR2 pathways have attracted interest, as abnormal tumour vasculature not only sustains growth but also restricts immune infiltration. This thesis explores whether co-targeting immune and vascular pathways, supplemented by physiological modulation through exercise, can improve therapeutic outcomes in mesothelioma. Chapter 2 establishes the rationale for combining anti-PD-L1 immunotherapy, anti-VEGFR2 anti-angiogenic therapy, and exercise, highlighting the interplay between angiogenesis, immune evasion, and vascular normalisation as a strategy to enhance immune activity. In a subcutaneous mesothelioma model (Chapter 3), dual blockade of PD-L1 and VEGFR2 significantly delayed tumour progression, extended survival, and induced vascular changes consistent with normalisation. CD4⁺ T cell depletion experiments revealed their central role in mediating therapeutic benefit and maintaining vascular integrity, underscoring the interdependence of immune and vascular mechanisms. To explore physiological modulation, Chapter 4 examined the addition of high-intensity interval training to combination therapy. Exercise preserved physical fitness and modestly influenced vascular structure but did not further enhance tumour control or survival in this model. These findings suggest that exercise-induced physiological changes may not always synergise with immunotherapy and should be tailored to tumour-specific contexts. Recognising the limitations of subcutaneous models, Chapters 5 and 6 describe the development of a minimally invasive intrapleural injection protocol to generate an orthotopic mesothelioma model and the re-evaluation of combination therapy within this context. In contrast to subcutaneous results, the therapy failed to improve survival or promote vascular normalisation, emphasising the critical influence of anatomical context on therapeutic efficacy. Together, this work demonstrates that effective mesothelioma treatment may require multifaceted approaches addressing immune, vascular, and physiological barriers. By integrating insights across diverse models, this dissertation provides a foundation for refining immune–vascular co-targeting and developing multimodal strategies to improve patient outcomes.